^
    Back
    Association details:
    Biomarker:EGFR R521K
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    486P - Genetic polymorphism profile associated with cetuximab efficiency in colorectal cancer patients from Kazakhstan

    Published date:
    09/14/2020
    Excerpt:
    According to log-additive genetic modelling of inheritance we found that rs2227983 had a significant association with cetuximab efficiency (P = 0.016) and showed a highly significant inheritance codominant model with odds ratio (OR) 3.55 (P= 0.018).